Novel Drug Development of the Next-Generation T790M Mutant Specific Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for the Treatment of Advanced Non-Small Cell Lung Cancer
Toshio Shimizu* and Kazuhiko Nakagawa
Department of Medical Oncology, Kindai University, Japan
- *Corresponding Author:
- Toshio Shimizu
Department of Medical Oncology
Kindai University Faculty of Medicine
377-2 Ohnohigashi, Osaka-Sayama City
Osaka 5898511, Japan
E-mail: [email protected]
Received Date: February 09, 2016 Accepted Date: March 10, 2016 Published Date: March 14, 2016
Citation: Shimizu T, Nakagawa K (2016) Novel Drug Development of the Next-Generation T790M Mutant Specific Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for the Treatment of Advanced Non-Small Cell Lung Cancer. Biochem Anal Biochem 5:258. doi: 10.4172/2161-1009.1000258
Copyright: © 2016 Shimizu T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Lung cancer is a leading cause of cancer death worldwide. Lung cancer accounts for over 1 million mortalities annually and non-small cell lung cancer (NSCLC) accounts for almost 85% of all cases. Epidermal growth factor receptor (EGFR) mutations are found in approximately 10% and 30% of patients with NSCLC in North American/European and East Asian countries, respectively.